Drugmaker Genentech will pay the government $67 million to settle allegations that it oversold the effectiveness of one of its cancer drugs.
Pfizer's $160 billion deal to acquire Irish drugmaker Allergan got a lot of attention for the tax advantages Pfizer would enjoy from moving its New Jersey headquarters overseas to Dublin. There wasn't much talk, though, about how much the deal would expand Pfizer's footprint in biosimilars.
Genentech, the maker of Avastin and other pricey cancer drugs, paid physicians and teaching hospitals more than any other drug or device company did in 2014, according to data published last week on the CMS' Open Payments website.
The federal government is launching a very different kind of cancer study that will assign patients drugs based on what genes drive their tumors rather than the type.
A comparative-effectiveness test of three popular drugs used to treat a common diabetic eye disorder found all three drugs improved eyesight among diabetics with mild vision loss, but the most expensive drug delivered the best outcomes among subjects with the worst vision.
A new health insurance exchange announced last week by a large retailer is betting that analysts who predict that roughly 40 million people will buy their health plans through a private online marketplace by 2018 are right.
A group of hospitals that participate in the federal 340B drug-discount program have joined the debate about Genentech's decision to distribute three of its most expensive and commonly used cancer drugs through specialty distributors rather than standard wholesalers.
Consumers are highly optimistic about wearable devices' potential to improve healthcare, even though most now are not using wearables to track their own health, PricewaterhouseCoopers Health Research Institute says in a new report.
Pharmaceutical giant Genentech has come under a maelstrom of criticism from hospitals for its decision to change its distribution methods for three widely used cancer drugs, and now the nation's largest not-for-profit health system is responding with a bold message.
Drugmaker Genentech is changing the way it ships three high-profile cancer drugs to hospitals, which are concerned that the new process will grossly inflate their already high costs and potentially affect patient care. Genentech contends the change is designed to ensure patient safety and access to...
Google's ambitious health startup is teaming up with biotechnology drugmaker AbbVie in a $500 million joint venture that will try to develop new ways to treat cancer and other diseases such as Alzheimer's.
Memorial Sloan-Kettering Cancer Center saw an 89.1% increase in its operating surplus in the first half of the year from improved payment rates and higher outpatient volume.